Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals to Overweight and raised its price target to $18, citing an attractive entry point as the stock trades down 32% year-to-date despite strong fundamentals. The firm expects significant volume and revenue growth for 2026, with management guiding $320–$345 million in net revenue and aiming for operating profitability by Q3 2026. Phathom’s key drug VOQUEZNA shows strong prescription momentum, and exclusivity until 2032 supports long-term growth. Risks include negative equity and debt obligations, but upcoming weekly prescription data could signal a positive turnaround.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
